Darigabat is a small molecule commercialized by Cerevel Therapeutics, with a leading Phase II program in Seizures. According to Globaldata, it is involved in 16 clinical trials, of which 11 were completed, 3 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Darigabats valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Darigabat is expected to reach an annual total of $112 mn by 2036 in the US based off GlobalDatas Expiry Model. The drugs revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drugs phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Darigabat Overview
Darigabat (CVL-865) is under development for the treatment of panic disorder and drug-resistant focal onset seizures. It is administered orally as a tablet. The drug candidate specifically targets alpha 2,3 and 5 subunits of GABA-A receptor to overcome the significant side effects associated with alpha 1 binding. It was under development for the treatment for chronic low back pain and generalized anxiety disorder.
Cerevel Therapeutics Overview
Cerevel Therapeutics (Cerevel) is a clinical-stage biopharmaceutical company that develops therapies to treat neuroscience diseases. The companys product pipeline includes various drug candidates such as Emraclidine for treatment of schizophrenia and Alzheimers disease psychosis; and Darigabat to treat epilepsy and panic disorder. Cerevels pipeline also includes Tavapadon drug candidate for treatment of both early-and late-stage Parkinsons disease; and CVL-871 to treat dementia-related apathy. The company is also developing other programs such as CVL-354, PDE4 inhibitor, and M4 Agonist for therapeutic areas of major depressive disorder (MDD), psychiatric, neuroinflammatory disorder, and neurological indications. Cerevel is headquartered in Cambridge, Massachusetts, the US.
The operating loss of the company was US$447.3 million in FY2023, compared to an operating loss of US$367.9 million in FY2022. The net loss of the company was US$432.8 million in FY2023, compared to a net loss of US$351.5 million in FY2022.
For a complete picture of Darigabats valuation, buy the drugs risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.